Trial Profile
A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms RETRO-idel
- Sponsors Gilead Sciences
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 11 Apr 2019 Status changed from recruiting to completed.
- 11 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.